CAP-GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP-GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.
Follow CEVEC on LinkedIn.
Management
DR. NICOLE FAUST
CEO & CSO
DR. NICO SCHEER
Chief Business Officer
DR. NADINE SANDHÖFER
Director QA and Regulatory Affairs
Board
BART BERGSTEIN
Cofounder of Forbion Capital Partners
Former Life Science Venture Capitalist
CHRISTIAN LEIKERT
Investment Manager
at Creathor Venture
DR. ARISTOTELIS NASTOS
Head of Life Sciences
at NRW Bank Venture Fund
DR. JOACHIM RAUTTER
Partner at PEPPERMINTVENTURE PARTNERS
Chairman of the Board
DR. KLAUS ZIMMERMANN
Barrister-at-law
Scientific Advisory Board CAP®Go
PROF. DR. JÜRGEN HUBBUCH
Professor at Karlsruhe Institute of Technology
Head of the Institute of Engineering in Life
Section IV: Biomolecular Separation Engineering
PROF. DR. THOMAS NOLL
Professor and Chair for Cell Culture Technology
University of Bielefeld
Franz Nothelfer
Former Associate Director Protein Science
Boehringer Ingelheim Pharma GmbH & Co.KG
Scientific Advisory Board CAP®GT
PROF. DR. STEFAN KOCHANEK
Professor at the University of Ulm
and Director of the Department of Gene Therapy
DR. OTTO MERTEN
Specialist in gene therapy/vector manufacturing
Miltenyi Biotec
Dr. J. Fraser Wright
Professor of Pediatrics
Center for Definitive and Curative Medicine
Stanford University School of Medicine
Investors
GAT Holding (Switzerland), CEVEC’s Chief Executive Officer and Chief Scientific Officer as well as other private investors are complementing the investor base of CEVEC Pharmaceuticals GmbH